Skip to main content

Asthma Management in the Era of Targeted Therapy: Using Phenotype and Biomarkers to Individualize Management


A Series of CME-certified, MOC-eligible Live Webinars

TO REGISTER:
Click here to complete your registration.


DATE AND TIME
Saturday, January 23, 2021
10:00 - 11:00 AM ET (9:00 - 10:00 AM CT / 7:00 - 8:00 AM PT)
Hosted by: Alabama Society of Allergy, Asthma, and Immunology

AGENDA
Welcome and Introductions
Pathogenesis of Asthma
Ensuring Timely and Accurate Diagnoses of Severe Asthma
Targeted Approach to Controlling Asthma Based on Phenotype and Severity
Patient Engagement and Strategies to Improve Adherence
Q&A Session and Activity Roundup

PROGRAM DESCRIPTION
Optimal asthma management involves control of asthma symptoms and reduction of the risk of future asthma exacerbations. However, asthma is a heterogeneous condition and the relationship between daily symptoms and exacerbations varies between different phenotypes and disease severities. Often standard treatment approaches are uniformly used, irrespective of the inflammatory pathway involved and the clinical phenotype. Thus, a significant proportion of patients with severe asthma have inadequately controlled disease.

Patients with severe, persistent asthma (~4%-10% of all asthma cases) are managed by Global Initiative for Asthma (GINA) steps 4 or 5. These guidelines recommend a phenotypic assessment and selection of additional treatment based on the results of testing. This activity, “Asthma Management in the Era of Targeted Therapy: Using Phenotype and Biomarkers to Individualize Management,” will help allergists, immunologists, and other clinicians to diagnose severe asthma, use clinical presentation and biomarker results to determine asthma phenotype, and use this information to develop appropriate individualized management plans for their patients with severe asthma.

STEERING COMMITTEE
Leonard B. Bacharier, MD
Professor of Pediatrics
Director - Center for Pediatric Asthma Research
Scientific Director - Center for Clinical and Translational Research
Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center
Nashville, TN

Leonard B. Bacharier, MD MD is the Professor of Pediatrics, Director of the Center for Pediatric Asthma Research and Scientific Director of the Center for Clinical and Translational Research at Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center in Nashville, TN. His research focuses on childhood asthma and he is an investigator for several National Institutes of Health (NIH)-funded asthma programs, including AsthmaNet, the Inner City Asthma Consortium, and PrecISE.

Dr. Bacharier is currently investigating the role of early infection with respiratory syncytial virus upon the subsequent development of asthma. He serves as an Associate Editor for the Journal of Allergy and Clinical Immunology, as a member of the Global Initiative for Asthma (GINA) Science Committee, and as Chair of the American Board of Allergy and Immunology.

Wanda Phipatanakul, MD, MS
Professor of Pediatrics
Harvard Medical School
Director, Asthma Clinical Research Center
Boston Children's Hospital
Boston, MA


Wanda Phipatanakul, MD, MS
is Director of the Asthma Clinical Research Center at Boston Children’s Hospital and Professor of Pediatrics at Harvard Medical School. She has dedicated her career to reducing and preventing asthma and allergic diseases.

Originally from St. Louis, she earned her medical degree from Loma Linda University and completed her residency in pediatrics at Children’s Hospital Los Angeles in 1997. After a fellowship in immunology at Johns Hopkins University, she joined the faculty in the Division of Immunology and Allergy at Boston Children’s and Harvard Medical School, where she has remained for the past 19 years.

Dr. Phipatanakul has built a deep network of community relationships and conducts both school- and home-based asthma studies in children. She has also had continuous National Institutes of Health (NIH) funding for nearly 20 years. She leads the National Institute of Allergy and Infectious Diseases (NIAID) School Inner-City Asthma Intervention Study and the National Heart, Lung, and Blood Institute (NHLBI) Environment Assessment of Sleep in Youth. She is the overall Principal Investigator for an NIAID-funded, nationwide, multicenter asthma-prevention study evaluating omalizumab (anti-IgE) in preventing the atopic march and asthma.

Most recently, Dr. Phipatanakul was awarded an NIAID U01 evaluating whether patients carrying an IL4RαR576 gene variant will have a greater response to dupilumab. She leads her Center as Pediatric PI in multiple NHLBI asthma and prevention networks, including Precise, and has authored more than 220 publications in scientific journals, including JAMA and the New England Journal of Medicine. She is passionate about successfully mentoring the next generation of investigators, serving the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American Board of Allergy and Immunology (ABAI) in support of her specialty, and serving as a role model to others balancing work and family.

TARGET AUDIENCE
This activity is intended for allergists, immunologists, and other clinicians involved in the diagnosis and treatment of patients with severe asthma.

LEARNING OBJECTIVES
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

  • Use a patient’s clinical presentation and predictive biomarkers to determine asthma phenotype
  • Identify patients with severe asthma using the latest guideline recommendations
  • Differentiate among the various subtypes (e.g. eosinophilic), and phenotypes or endotypes of asthma
  • Develop personalized management plans incorporating clinical phenotype, biomarkers, and the mechanism of action, efficacy, and safety profiles of available pharmacologic and biologic agents
  • Incorporate strategies to engage patients in their care, improving disease understanding and adherence to treatment

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF ALLERGY AND IMMUNOLOGY (ABAI) MOC POINTS
Diplomates of the American Board of Allergy and Immunology (ABAI) must attest to obtaining 25 hours of Allergy/Immunology-specific CME credits from accredited organizations every year in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified allergists and immunologists in contributing towards this MOC requirement set forth by the ABAI.

DISCLAIMER
These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. Trustees of Boston University makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will trustees of Boston University be liable to anyone for any decision made or action take in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

DISCLOSURE
This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

FACULTY DISCLOSURES
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Leonard B. Bacharier, MD: Consultant: Aerocrine, AstraZeneca, Boehringer Ingelheim, Genentech/Novartis, GlaxoSmithKline, Sanofi/Regeneron, Teva; Speaker: AstraZeneca, GlaxoSmithKline, Novartis, Sanofi/Regeneron; Advisory Board: Circassia, Merck, Sanofi/Regeneron, Vectura; Data Safety Monitoring Board: DBV Technologies

Wanda Phipatanakul, MD, MS: Grant/Research Consultant: Genentech, Novartis, Regeneron, Sanofi 

Hasmeena Kathuria, MD, BUSM CME Course Director: Nothing to disclose

NON-FACULTY CONTENT CONTRIBUTORS
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Terry Ann Glauser, MD, MPH; Blair St. Amand; Elizabeth Drury; Natalie Sanfratello, MPH: Nothing to disclose

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of a
pproved uses.

SYSTEM CHECK
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
There is no fee for this activity. To receive credit, participants must register, view the live CME activity in its entirety, and then complete the post-test with a score of 70% or better and the evaluation. The estimated time for completion of this activity is 1 hour. To receive a certific
ate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

Jointly provided by Boston University School of Medicine and Rockpointe



This educational activity is supported by an educational grant from GlaxoSmithKline and Novartis Pharmaceuticals Corporation.